Amicus Therapeutics is an American biopharmaceutical company, centered in Cranbury, New Jersey. The company specializes in rare disorders, with a special focus on lysosomal storage disorders. The company’s product development takes place mainly in the Chaperone-

Advanced Replacement Therapy with a specialty in enzyme replacement therapy. The most advanced product of Amicus Therapeutics is migalastat, a chaperone treatment for Fabry disease. Its lead biologic program is ATB200/AT2221, a Pomp disease ERT.


As a global biotechnology company, the team of Amicus Therapeutics has a big and bold vision on treating rare diseases (MarketWatch). The key points of the company are the treatment of rare and devastating diseases, the technology to be the best, and the clinical data that is meaningful to patients.


The CEO and chairman of Amicus Therapeutics is John F. Crowley, the father of two children diagnosed with Pompe disease, a severe neuromuscular disorder ( For this reason in 1998 he started the journey at aiming to find a cure for them. He has been in this position since 2005.


Amicus Therapeutics is dedicated to its ethics and values. The team is held together with strong bonds of friendship. The company shares one set of work principles and expectations, which unifies the company, no matter where it is. Amicus Therapeutics does not engage in bribery and corruption. Patients and their representing advocacy organizations are the centers of the company’s incentives. It works closely with HCPs and HCOs. These interactions make sure there is a transparency in the way clinical trials are conducted, how medicines are used, and recent information on research. The company thus commits to giving truthful information about its products and put fair market prices on its services and products.


Amicus Therapeutics contributes to charitable organizations and non-profit healthcare organizations that help people with rare diseases. The reason is the shared mission of improving the health of people.